Statistics

Total Visits

Views
Apremilast, an oral phosphodiesterase 4 inhibitor, is associated with long-term (52-week) improvement in measures of disease activity in patients with psoriatic arthritis: Results from 3 phase 3, randomized, controlled trials122

Select a period of time:

Number of views in the range

Views
Apremilast, an oral phosphodiesterase 4 inhibitor, is associated with long-term (52-week) improvement in measures of disease activity in patients with psoriatic arthritis: Results from 3 phase 3, randomized, controlled trials30

Views

Views
September 20252
October 20251
November 20255
December 20254
January 202617
February 20261
March 20260
Download CSV file
 untranslated
 untranslated

Top country views

Views
United States15
Brazil4
Venezuela2
Ecuador2
Argentina1
Canada1
Congo1
Egypt1
United Kingdom1
Hong Kong1
 

Top cities views

Views
San Jose4
Ashburn3
Guayaquil2
Barquisimeto2
Al Ma`adi1
Brazzaville1
Dallas1
Guarapuava1
Los Angeles1
North Bergen1